Read More 2 minute read Analyst Color Analyst Ratings Earnings Movers News Price Target Reiteration Top Stories Trading Ideas 5 HubSpot Analysts Raise Their Price Targets After Better-Than-Expected Earnings By Priya Nigam February 17, 11:16 AM Shares of HubSpot Inc (NYSE: HUBS) continued spiked on Friday, after the company reported quarterly results. HUBS
Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on MagnaChip Semiconductor, Maintains $13 Price Target By Benzinga Newsdesk February 17, 10:32 AM Needham analyst Rajvindra Gill reiterates MagnaChip Semiconductor (NYSE:MX) with a Buy and maintains $13 price target. MX
Read More 1 minute read Analyst Ratings News Price Target Reiteration EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target By Benzinga Newsdesk February 17, 9:57 AM EF Hutton analyst Michael King reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $6.85 price target. JSPR
Read More 1 minute read Analyst Ratings News Price Target Reiteration Mizuho Reiterates Neutral on Syneos Health, Maintains $38 Price Target By Benzinga Newsdesk February 17, 9:51 AM Mizuho analyst Ann Hynes reiterates Syneos Health (NASDAQ:SYNH) with a Neutral and maintains $38 price target. SYNH
Read More 1 minute read Analyst Ratings News Price Target Reiteration Credit Suisse Reiterates Outperform on AMN Healthcare Services, Maintains $147 Price Target By Benzinga Newsdesk February 17, 8:52 AM Credit Suisse analyst Jonathan Yong reiterates AMN Healthcare Services (NYSE:AMN) with a Outperform and maintains $147 price target. AMN
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $36 Price Target By Benzinga Newsdesk February 17, 7:55 AM HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $36 price target. TVTX
Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on Cara Therapeutics, Maintains $26 Price Target By Benzinga Newsdesk February 17, 7:49 AM Needham analyst Joseph Stringer reiterates Cara Therapeutics (NASDAQ:CARA) with a Buy and maintains $26 price target. CARA
Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on DraftKings, Maintains $20 Price Target By Benzinga Newsdesk February 17, 7:33 AM Needham analyst Bernie McTernan reiterates DraftKings (NASDAQ:DKNG) with a Buy and maintains $20 price target. DKNG
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $32 Price Target By Benzinga Newsdesk February 17, 7:20 AM HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $32 price target. ALKS
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Inozyme Pharma, Maintains $20 Price Target By Benzinga Newsdesk February 17, 7:18 AM HC Wainwright & Co. analyst Edward White reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $20 price target. INZY